The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ELTX | +102.93% | N/A | N/A | -47% |
| S&P | +16.9% | +95.99% | +14.39% | +59% |
Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Boston, MA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.28M | 4.1% |
| Market Cap | $123.50M | 193.7% |
| Market Cap / Employee | $3.86M | 0.0% |
| Employees | 32 | 0.0% |
| Net Income | -$10.56M | -46.1% |
| EBITDA | -$9.81M | 7.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $22.09M | 478.1% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $13.95M | 150.7% |
| Short Term Debt | $0.95M | 11.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -241.23% | -96.3% |
| Return On Invested Capital | -145.66% | -130.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$8.95M | 0.2% |
| Operating Free Cash Flow | -$8.95M | -0.2% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -31.24 | -2.90 | -6.01 | 13.85 | 60.53% |
| Price to Tangible Book Value | -31.24 | -2.90 | -6.01 | 13.85 | 60.52% |
| Enterprise Value to EBITDA | -6.67 | -4.82 | -6.36 | -11.91 | 158.41% |
| Return on Equity | -353.0% | -170157.4% | -744.6% | -60013.2% | 34172.14% |
| Total Debt | $26.05M | $26.04M | $5.79M | $14.90M | 132.15% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
